Studie van lumateperon als aanvullende therapie bij de behandeling van patiënten met depressieve stoornis
Een gerandomiseerde, dubbelblinde, placebogecontroleerde multicenterstudie om de werkzaamheid en veiligheid van lumateperon te beoordelen als aanvullende therapie bij de behandeling van patiënten met depressieve stoornis
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 3
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Study Contact
- Telefoonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studie Locaties
-
-
-
Cherven Bryag, Bulgarije, 5980
- Werving
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgarije, 6600
- Werving
- Medical Center Lifemed
-
Pleven, Bulgarije, 5800
- Werving
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgarije, 4004
- Werving
- Medical Center Mentalcare OOD
-
Sofia, Bulgarije, 1680
- Werving
- Medical Center Intermedica, OOD
-
Sofia, Bulgarije, 1510
- Werving
- Medical Center Hera EOOD
-
Sofia, Bulgarije, 1202
- Werving
- MHC - Sofia, EOOD
-
Sofia, Bulgarije, 1431
- Beëindigd
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgarije, 6003
- Voltooid
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgarije, 9020
- Werving
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Douai, Frankrijk, 59500
- Werving
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, Frankrijk, 44093
- Werving
- CHU de Nantes hotel Dieu
-
Nîmes, Frankrijk, 30029
- Werving
- Hopital Caremeau
-
Paris, Frankrijk, 75012
- Werving
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, Frankrijk, 86021
- Werving
- CH Henri Laborit
-
-
-
-
-
Ahmedabad, Indië, 380008
- Geschorst
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, Indië, 380009
- Geschorst
- Sushrusha Navneet Memorial Hospital
-
Ajmer, Indië, 305001
- Geschorst
- J L N Medical College and Attached Hospitals
-
Bikaner, Indië, 334001
- Werving
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, Indië, 413102
- Werving
- Baramati Hospital
-
Chandigarh, Indië, 160012
- Werving
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, Indië, 781032
- Voltooid
- Gauhati Medical College and Hospital
-
Kolhāpur, Indië, 416001
- Werving
- Swastik Hospital
-
Nagpur, Indië, 440001
- Werving
- KIMS-Kingsway Hospitals
-
Palsāna, Indië, 394315
- Werving
- Divyam Hospital
-
Pune, Indië, 411011
- Werving
- Shree Samarth Hospital
-
Rajkot, Indië, 360001
- Voltooid
- Nagecha Hospital
-
Wardha, Indië, 442004
- Geschorst
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Litouwen, LT-44279
- Voltooid
- Romuvos Klinika, JSC
-
Ziegzdriai, Litouwen, 53136
- Voltooid
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Servië, 11000
- Werving
- University Clinical Center of Serbia
-
Belgrade, Servië, 11000
- Werving
- Institute of Mental Health Serbia
-
Belgrade, Servië, 11000
- Werving
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Servië, 26220
- Werving
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Servië, 34000
- Werving
- University Clinical Center Kragujevac
-
Kragujevac, Servië, 34000
- Werving
- University Clinical Center Kragujevac 1
-
Niš, Servië, 18000
- Werving
- University Clinical Center NIS 1
-
Niš, Servië, 18000
- Werving
- University Clinical Center NIS
-
Novi Kneževac, Servië, 23330
- Werving
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, Spanje, 08036
- Werving
- Hosp. Clinic de Barcelona
-
Barcelona, Spanje, 08035
- Werving
- Hosp Univ Vall D Hebron
-
Madrid, Spanje, 28034
- Voltooid
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Spanje, 08208
- Werving
- Hosp.Univ.Parc Tauli
-
Zamora, Spanje, 49021
- Werving
- Hosp. Prov. de Zamora
-
-
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35801
- Werving
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, Verenigde Staten, 90660
- Werving
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, Verenigde Staten, 06030
- Werving
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, Verenigde Staten, 34711
- Beëindigd
- Vertex Clinical Research
-
Hialeah, Florida, Verenigde Staten, 33012
- Geschorst
- New Life Medical Research Center, Inc.
-
Miami, Florida, Verenigde Staten, 33122
- Werving
- Premier Clinical Research Institute
-
Miami, Florida, Verenigde Staten, 33137
- Werving
- Miami Jewish Health System
-
Tampa, Florida, Verenigde Staten, 33629
- Werving
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Werving
- The Emory Clinic
-
Decatur, Georgia, Verenigde Staten, 30030
- Werving
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Beëindigd
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, Verenigde Staten, 66210
- Werving
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, Verenigde Staten, 01844
- Beëindigd
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, Verenigde Staten, 63368
- Werving
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Verenigde Staten, 08755
- Werving
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11235
- Werving
- SPRI Clinical Trials, LLC
-
New York, New York, Verenigde Staten, 10036
- Werving
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, Verenigde Staten, 44012
- Werving
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, Verenigde Staten, 45219
- Werving
- University of Cincinnati Medical Center
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77081
- Werving
- DM Clinical Research
-
Mansfield, Texas, Verenigde Staten, 76063
- Voltooid
- Hawkins Psychiatry, PC
-
Richardson, Texas, Verenigde Staten, 75080
- Werving
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98007
- Werving
- Northwest Clinical Research Center
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
|
Matching capsules administered orally, once daily |
|
Experimenteel: Lumateperon 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Tijdsspanne: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Tijdsspanne: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- ITI-007-505
- ITI-007-505 (Andere identificatie: Janssen Research & Development, LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .